Atlas Trials

Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Clinical trial NCT02579369 · COMPLETED

Trial details

NCT number
NCT02579369
Sponsor
Anterogen Co., Ltd.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Dystrophic Epidermolysis Bullosa
Start date
2015-12-08
Primary completion
2016-04-01
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.